Connect with us

Hi, what are you looking for?

Tuesday, Jan 31, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Tetra Bio-Pharma enters Australia via new subsidiary acquisition

Canadian company set to focus clinical trials down under, announces regulatory update

Tetra Bio-Pharma enters Australia via new subsidiary acquisition
Photo via Unsplash - Joey Csunyo

Ottawa-based cannabinoid pharmaceutical Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) has launched a new research-focused subsidiary in Australia.

On Monday, the developer announced the debut of its new subsidiary Tetra Bio-Pharma Australia Pty Ltd (TBP-AU) which will focus on clinical trials in the country.

TBP-AU will be the second foreign subsidiary that Tetra has created following its recent decision to enter into a partnership with Cannvalate Pty Ltd to help facilitate clinical trials in Australia more efficiently. This new Australian company will be reaping the rewards of having a 43.5 per cent tax credit on all finances invested in those trials nationally.

The company has also expressed enthusiasm by announcing that it has successfully finished its annual review process with Health Canada to retain its Drug Establishment License (DEL). Tetra satisfied the regulatory requirements needed to maintain its license and distribute medications like REDUVO.

The Ontario-based company is engaged in a clinical trials program approved by Health Canada and the Food and Drug Administration (FDA).

Read more: Tetra Bio-Pharma to receive $4.5M loan from Quebec government

Read more: Tetra Bio-Pharma partners with Avicanna to bring cannabinoid medical products to LATAM

On Dec. 30, 2020, Tetra applied to Health Canada with an initial New Drug Submission (NDS) for REDUVO, a soft gel orally administered THC pill treatment used to alleviate the nasty side effects of chemotherapy and the symptoms associated with HIV infection.

Two years later, Tetra is still in discussions with Health Canada attempting to address concluding commentary on their submission. The company has expressed that REDUVO is an imperative priority and desires to launch production immediately following regulatory approval.

“We look forward to working with our strategic partners and building value for our current and future investors. These are very exciting times for us as we continue to drive scientific excellence and deliver on the promise of cannabinoid-derived transformative medicines to improve patient health and quality of life,” said CEO, Guy Chamberland.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook



Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Gryphon and Akerna will create a carbon-neutral bitcoin miner that’s committed to ESG practices


Individuals previously convicted of cannabis possession under 2 oz will receive automatic expungement as well


The first cultivars will include Pink Kush, Jet Fuel Gelato and Black Cherry Punch


The company now expects to generate over $30M in revenue next year